...
首页> 外文期刊>Current hypertension reports. >Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention
【24h】

Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention

机译:预防卒中中的血压控制与房颤管理

获取原文
获取原文并翻译 | 示例
           

摘要

Hypertension is one of the major risk factors for atrial fibrillation which in turn is the most prevalent concomitant condition in hypertensive patients. While both these pathological conditions are independent risk factors for stroke, the association of hypertension and atrial fibrillation increases the incidence of disabling strokes. Moreover, documented or silent atrial fibrillation doubles the rate of cardiovascular death. Lowering blood pressure is strongly recommended, particularly for primary stroke prevention. However, a relatively small percentage of hypertensive patients still achieve the recommended blood pressure goals. The management of atrial fibrillation with respect to stroke prevention is changing. New oral anticoagulants represent a major advancement in long-term anticoagulation therapy in non valvular atrial fibrillation. They have several benefits over warfarin, including improved adherence to the anticoagulation therapy. This is an important issue since non-adherence to stroke prevention medications is a risk factor for first and recurrent strokes.
机译:高血压是房颤的主要危险因素之一,而房颤又是高血压患者最普遍的伴随疾病。尽管这两种病理状况都是中风的独立危险因素,但高血压和心房纤颤的相关性增加了中风致残性卒中的发生率。而且,有案可查的或无声的房颤会使心血管死亡的速度增加一倍。强烈建议降低血压,尤其是对于初级卒中的预防。但是,相对较小比例的高血压患者仍能达到建议的血压目标。关于预防中风的心房颤动的管理方法正在改变。新的口服抗凝剂代表了非瓣膜性房颤长期抗凝治疗的重大进展。它们比华法林具有多种优势,包括改善对抗凝疗法的依从性。这是一个重要的问题,因为不遵守中风预防药物是初发和复发性中风的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号